Progesterone News and Research

RSS

Study confirms risk of triple-negative breast cancer among obese, physically inactive women

New findings published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, confirm the risk of breast cancer among women who are obese and not physically active, and suggests additional mechanisms beyond estrogen.

1 Mar 2011

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon but particularly aggressive subtype of the disease.

24 Feb 2011

Women need good nutrition and regular exercise

Obesity levels are at an all-time high among men, women, and children in the United States. The need for good nutrition and regular exercise is paramount for maintaining proper health and for keeping those extra pounds at bay, especially for women.

11 Feb 2011

Three proteins responsible for success of progesterone treatments in prevention of preterm labor

Research presented today at the 31st Annual meeting of the Society for Maternal-Fetal Medicine (SMFM) ― The Pregnancy Meeting™ has found that three proteins known as XIAP, BID, and Bcl-2 are responsible in part for the success of progesterone treatments in the prevention of preterm labor. They may also play an important role in triggering normal labor.

10 Feb 2011

Hormone 17-Hydroxyprogesterone does not reduce rate of preterm delivery in twin pregnancies: Study

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that the use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins.

10 Feb 2011

TS Wiley develops HRT protocol using Idiom Decision Manager tool

The Wiley Protocol is a trademarked, patent protected bio-identical hormone replacement therapy delivery system consisting of biomimetic estradiol and progesterone in a topical cream preparation – dosed to mimic the natural hormones produced by a woman's body when she was in her prime. The Wiley Protocol is the brainchild of TS Wiley, a popular author and frequent speaker at medical seminars around the world.

7 Feb 2011

March of Dimes appreciates FDA for approving new drug to prevent preterm births

The first-ever drug known to prevent some preterm births, which won market approval today from the Food and Drug Administration, was welcomed by the March of Dimes.

5 Feb 2011

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.

1 Feb 2011

Research on triple negative disease can benefit patients with breat cancer

Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

1 Feb 2011

Aging-associated protein deficiency may lead to positive breast cancer in women

The most common type of breast cancer in older women - estrogen and progesterone receptor positive breast cancer - has been linked to a protein that fends off aging-related cellular damage.

28 Jan 2011

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival

28 Jan 2011

Tamoxifen may reduce individual's risk of death from lung cancer: New study

A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer.

24 Jan 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

6 Jan 2011

Fruit fly faeces provides answers to pregnant women's bloating and constipation

Clues about how the human gut helps regulate our appetite have come from a most unusual source - fruit fly faeces. Scientists at the University of Cambridge are using the fruit fly to help understand aspects of human metabolism, including why pregnant women suffer from bloating and constipation, and even the link between a low calorie diet and longevity.

5 Jan 2011

Hormone enhanced meat taken off shelves at Coles

Hormonal growth enhancers banned three decades ago in Europe after being linked to health risks including breast cancer, kidney disease and birth defects are still being used in Australia to fatten beef, a federal farm chemical survey reveals.

28 Dec 2010

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.